Business Wire

Vodafone Spain and Twilio Partner to Offer Secure and Interactive RCS Messaging to Businesses in Spain

23.10.2025 10:00:00 CEST | Business Wire | Press Release

Share

Twilio, the customer engagement platform that powers personalised, real-time experiences for today's leading brands, has announced an extended partnership with Vodafone Spain, one of the country's leading telecommunications operators. This will enable Spanish businesses to access Rich Communication Services (RCS) messaging, revolutionising the way they interact with their customers through rich, interactive and secure communications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251023623745/en/

Vodafone Spain has relied on Twilio's global expertise to accelerate the adoption of this next-generation messaging solution, positioning it as the new standard for business communication in the Spanish market.

A much needed evolution for mobile communication

In a world where personalisation and trust are essential for brand to consumer relationships, RCS offers an experience that goes beyond the capabilities of traditional SMS. According to Twilio's State of Customer Engagement 2025 report, 81% of consumers prefer RCS over SMS, and 71% of businesses plan to adopt it in the next year.

With advanced features such as images, videos, product carousels, interactive buttons and verified senders, RCS transforms messages into more dynamic, human and relevant communications that generate greater impact and engagement. In addition, the ability of RCS to measure detailed metrics such as open rates, clicks and interactions allows businesses to optimise their campaigns in real time, maximising return on investment (ROI).

Trust and transparency have become central to customer expectations as spam and phishing attempts increase. RCS fully responds to these risks by enhancing the credibility and impact of brand communications.

Key benefits for businesses and users

  • Enhanced interactivity: RCS allows actionable buttons to be included directly in messages, facilitating actions such as purchases, reservations or surveys without having to leave the conversation.
  • Verified identity: Through branded messaging, a business can attach its name, brand logo, a tagline, and a verified badge to every text it sends, which means customers instantly recognise and can verify who’s reaching out.
  • Enriched experience: Multimedia content such as images, GIFs and videos enhances the user experience, making interactions more engaging and memorable.
  • Two-way communication: RCS encourages real-time conversations, allowing customers to resolve queries or make enquiries directly from the chat.
  • Advanced personalisation: Thanks to the integration of contextual data like purchase history, browsing history, and preference, companies can tailor messages to the specific preferences and needs of each customer.

A strategic collaboration to transform communications in Spain

Luis Suñer, Head of Wholesale MVNOs and Third Party Deals at Vodafone Spain, highlights: "We are delighted to partner with Twilio to bring RCS messaging to our business customers in Spain. This technology not only greatly enhances the quality of interactions between brands and consumers, but also reinforces trust and security while enhancing brand credibility. With RCS, businesses will be able to connect with their customers in a more relevant, dynamic and effective way."

Twilio’s EMEA VP of Marketing, Peter Bell, states: "This expanded partnership with Vodafone Spain is especially timely given the holiday season is upon us and is a make-or-break time for brands. With brands using RCS, especially for holiday messages, the engagement channel boasts 98% open rates and 45% response rates. Together with Vodafone, we are offering businesses a powerful tool to stand out in a competitive environment."

A promising future for business messaging

Thanks to this collaboration, Vodafone Spain customers will be able to harness the full potential of RCS to improve customer relationships, increase response rates and generate greater engagement. For users who do not yet have RCS-compatible devices, Twilio guarantees a smooth transition to the SMS format with the help of automatic failover, ensuring complete and continuous coverage.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251023623745/en/

Contacts

iperkins@twilio.com
00447931815123

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye